{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:26:05Z","timestamp":1791951965373,"version":"4.3.4"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40259-025-00742-0","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:45:12Z","timestamp":1757342712000},"page":"841-855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation"],"prefix":"10.1007","volume":"39","author":[{"given":"Federico","family":"Yandian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-209X","authenticated-orcid":false,"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"742_CR1","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1345\/aph.1G311","volume":"39","author":"KM Summers","year":"2005","unstructured":"Summers KM, Kockler DR. Rituximab treatment of refractory rheumatoid arthritis. Ann Pharmacother. 2005;39:2091\u20135. https:\/\/doi.org\/10.1345\/aph.1G311.","journal-title":"Ann Pharmacother"},{"issue":"105","key":"742_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"2024","author":"KDIGO","year":"2024","unstructured":"KDIGO. Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;2024(105):S1-69. https:\/\/doi.org\/10.1016\/j.kint.2023.09.002.","journal-title":"Kidney Int"},{"key":"742_CR3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736\u201345. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089.","journal-title":"Ann Rheum Dis"},{"key":"742_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/RHU.0000000000001877","volume":"29","author":"P Chen","year":"2023","unstructured":"Chen P, Zhou Y, Wu L, Chen S, Han F. Efficacy and safety of biologic agents for lupus nephritis: a systematic review and meta-analysis. J Clin Rheumatol. 2023;29:95\u2013100. https:\/\/doi.org\/10.1097\/RHU.0000000000001877.","journal-title":"J Clin Rheumatol"},{"key":"742_CR5","unstructured":"KDIGO 2024 Clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis."},{"key":"742_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W, Georges G, Schwaiger M, M\u00f6ssner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5:22\u201333. https:\/\/doi.org\/10.4161\/mabs.22771.","journal-title":"MAbs"},{"key":"742_CR7","unstructured":"Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. B cell trophic factors and B cell antagonism in autoimmune disease. 8. 2005."},{"key":"742_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","volume":"118","author":"G Niederfellner","year":"2011","unstructured":"Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies. Blood. 2011;118:358\u201367. https:\/\/doi.org\/10.1182\/blood-2010-09-305847.","journal-title":"Blood"},{"key":"742_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1182\/blood-2017-03-771832","volume":"130","author":"G Cartron","year":"2017","unstructured":"Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials? Blood. 2017;130:581\u20139. https:\/\/doi.org\/10.1182\/blood-2017-03-771832.","journal-title":"Blood"},{"key":"742_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nri2762","volume":"10","author":"KGC Smith","year":"2010","unstructured":"Smith KGC, Clatworthy MR. Fc\u03b3RIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10:328\u201343. https:\/\/doi.org\/10.1038\/nri2762.","journal-title":"Nat Rev Immunol"},{"key":"742_CR11","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","volume":"118","author":"SH Lim","year":"2011","unstructured":"Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118:2530\u201340. https:\/\/doi.org\/10.1182\/blood-2011-01-330357.","journal-title":"Blood"},{"key":"742_CR12","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1182\/bloodadvances.2022009548","volume":"7","author":"T Schieber","year":"2023","unstructured":"Schieber T, Li A, Lundberg J, Wiczer T, Voorhees T. Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders. Blood Adv. 2023;7:3431\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2022009548.","journal-title":"Blood Adv"},{"key":"742_CR13","doi-asserted-by":"crossref","unstructured":"Teeling JL, Mackus WJM, Wiegman LJJM, Van Den Brakel JHN, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 1. pp. 177. 2006.","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"742_CR14","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","volume":"115","author":"SA Beers","year":"2010","unstructured":"Beers SA, French RR, Chan HTC, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115:5191\u2013201. https:\/\/doi.org\/10.1182\/blood-2010-01-263533.","journal-title":"Blood"},{"key":"742_CR15","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1016\/j.molimm.2009.04.009","volume":"46","author":"J Du","year":"2009","unstructured":"Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009;46:2419\u201323. https:\/\/doi.org\/10.1016\/j.molimm.2009.04.009.","journal-title":"Mol Immunol"},{"issue":"3","key":"742_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3324\/haematol.2008.001024","volume":"94","author":"NA Johnson","year":"2009","unstructured":"Johnson NA, Leach S, Woolcock B, Deleeuw RJ, Bashashati A, Sehn LH, et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica. 2009;94(3):423\u20137. https:\/\/doi.org\/10.3324\/haematol.2008.001024.","journal-title":"Haematologica"},{"key":"742_CR17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002","author":"MS Cragg","year":"2003","unstructured":"Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003. https:\/\/doi.org\/10.1182\/blood-2002.","journal-title":"Blood"},{"key":"742_CR18","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","volume":"103","author":"MS Cragg","year":"2004","unstructured":"Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738\u201343. https:\/\/doi.org\/10.1182\/blood-2003-06-2031.","journal-title":"Blood"},{"key":"742_CR19","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.4049\/jimmunol.1600648","volume":"197","author":"EM Cook","year":"2016","unstructured":"Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, et al. Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions. J Immunol. 2016;197:1762\u201375. https:\/\/doi.org\/10.4049\/jimmunol.1600648.","journal-title":"J Immunol"},{"key":"742_CR20","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell - mediated B-cell cytotoxicity. Blood. 2010;115:4393\u2013402. https:\/\/doi.org\/10.1182\/blood-2009-06-225979.","journal-title":"Blood"},{"key":"742_CR21","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","volume":"117","author":"W Alduaij","year":"2011","unstructured":"Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117:4519\u201329. https:\/\/doi.org\/10.1182\/blood-2010-07-296913.","journal-title":"Blood"},{"key":"742_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/10428194.2013.797976","volume":"55","author":"TM Illidge","year":"2014","unstructured":"Illidge TM, Cheadle EJ, Honeychurch J. New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor. Leuk Lymphoma. 2014;55:3\u20134. https:\/\/doi.org\/10.3109\/10428194.2013.797976.","journal-title":"Leuk Lymphoma"},{"key":"742_CR23","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.aaz9356","volume":"367","author":"L Roug\u00e9","year":"2020","unstructured":"Roug\u00e9 L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367:1224\u201330. https:\/\/doi.org\/10.1126\/science.aaz9356.","journal-title":"Science"},{"key":"742_CR24","doi-asserted-by":"crossref","unstructured":"Kumar A, Planchais C, Fronzes R, Mouquet H, Reyes N. Binding mechanisms of therapeutic antibodies to human CD20 Downloaded from. 2020.","DOI":"10.1126\/science.abb8008"},{"key":"742_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/CCO.0000000000000107","volume":"26","author":"AL Gagez","year":"2014","unstructured":"Gagez AL, Cartron G. Obinutuzumab: A new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 2014;26:484\u201391. https:\/\/doi.org\/10.1097\/CCO.0000000000000107.","journal-title":"Curr Opin Oncol"},{"key":"742_CR26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.10.1453","author":"M Batten","year":"2000","unstructured":"Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. Baff mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000. https:\/\/doi.org\/10.1084\/jem.192.10.1453.","journal-title":"J Exp Med"},{"key":"742_CR27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754","author":"G Cartron","year":"2002","unstructured":"Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood. 2002. https:\/\/doi.org\/10.1182\/blood.V99.3.754.","journal-title":"Blood"},{"key":"742_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145633","author":"JD K\u00f6nitzer","year":"2015","unstructured":"K\u00f6nitzer JD, Sieron A, Wacker A, Enenkel B. Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro. PLoS ONE. 2015. https:\/\/doi.org\/10.1371\/journal.pone.0145633.","journal-title":"PLoS ONE"},{"key":"742_CR29","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/0091270009337512","volume":"49","author":"DD Wang","year":"2009","unstructured":"Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49:1012\u201324. https:\/\/doi.org\/10.1177\/0091270009337512.","journal-title":"J Clin Pharmacol"},{"key":"742_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","volume":"182","author":"CL Freeman","year":"2018","unstructured":"Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182:29\u201345. https:\/\/doi.org\/10.1111\/bjh.15232.","journal-title":"Br J Haematol"},{"key":"742_CR31","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1681\/ASN.2021040561","volume":"32","author":"P Ravani","year":"2021","unstructured":"Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, et al. Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial. J Am Soc Nephrol. 2021;32:2652\u201363. https:\/\/doi.org\/10.1681\/ASN.2021040561.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR32","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rav\u00e0 L, et al. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol. 2016;27:1811\u201322. https:\/\/doi.org\/10.1681\/ASN.2015050523.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/MNH.0000000000001039","volume":"34","author":"F Caravaca-Font\u00e1n","year":"2025","unstructured":"Caravaca-Font\u00e1n F, Yandian F, Fervenza FC. Updated diagnostic and therapeutic management for membranous nephropathy. Curr Opin Nephrol Hypertens. 2025;34:23\u201332. https:\/\/doi.org\/10.1097\/MNH.0000000000001039.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"742_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","volume":"84","author":"D Bhatia","year":"2018","unstructured":"Bhatia D, Sinha A, Hari P, Sopory S, Saini S, Puraswani M, et al. Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr Res. 2018;84:520\u20136. https:\/\/doi.org\/10.1038\/s41390-018-0088-7.","journal-title":"Pediatr Res"},{"key":"742_CR35","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.ajt.2024.01.036","volume":"24","author":"F Hullekes","year":"2024","unstructured":"Hullekes F, Uffing A, Verhoeff R, Seeger H, von Moos S, Mansur J, et al. Recurrence of membranous nephropathy after kidney transplantation: a multicenter retrospective cohort study. Am J Transplant. 2024;24:1016\u201326. https:\/\/doi.org\/10.1016\/j.ajt.2024.01.036.","journal-title":"Am J Transplant"},{"key":"742_CR36","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1600-6143.2011.03903.x","volume":"12","author":"EF Rodriguez","year":"2012","unstructured":"Rodriguez EF, Cosio FG, Nasr SH, Sethi S, Fidler ME, Stegall MD, et al. The pathology and clinical features of early recurrent membranous glomerulonephritis. Am J Transplant. 2012;12:1029\u201338. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03903.x.","journal-title":"Am J Transplant"},{"key":"742_CR37","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1111\/j.1600-6143.2009.02851.x","volume":"9","author":"ZM El-Zoghby","year":"2009","unstructured":"El-Zoghby ZM, Grande JP, Fraile MG, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant. 2009;9:2800\u20137. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02851.x.","journal-title":"Am J Transplant"},{"key":"742_CR38","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u00e0 M, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850\u201363. https:\/\/doi.org\/10.1681\/ASN.2013030251.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01797-7","author":"P Hansrivijit","year":"2020","unstructured":"Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol. 2020. https:\/\/doi.org\/10.1186\/s12882-020-01797-7.","journal-title":"BMC Nephrol"},{"key":"742_CR40","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","volume":"14","author":"C Xue","year":"2021","unstructured":"Xue C, Yang B, Xu J, Zhou C, Zhang L, Gao X, et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clin Kidney J. 2021;14:1042\u201354. https:\/\/doi.org\/10.1093\/ckj\/sfaa191.","journal-title":"Clin Kidney J"},{"key":"742_CR41","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1681\/ASN.0000000520","volume":"36","author":"P Gauckler","year":"2025","unstructured":"Gauckler P, Matyjek A, Kapsia S, Marinaki S, Quintana LF, Diaz MM, et al. Long-term outcomes of Rituximab-treated adult patients with podocytopathies. J Am Soc Nephrol. 2025;36:668\u201378. https:\/\/doi.org\/10.1681\/ASN.0000000520.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.05.013","author":"MJ Vargas-Brochero","year":"2025","unstructured":"Vargas-Brochero MJ, Lafaut E, Radhakrishnan Y, Russo I, Sethi S, Zand L, et al. Long-term outcome of adult patients with membranous nephropathy treated with Rituximab. Kidney Int Rep. 2025. https:\/\/doi.org\/10.1016\/j.ekir.2025.05.013.","journal-title":"Kidney Int Rep"},{"key":"742_CR43","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/ckj\/sfad122","volume":"16","author":"AD Morris","year":"2023","unstructured":"Morris AD, Floyd L, Woywodt A, Dhaygude A. Rituximab in the treatment of primary FSGS: time for its use in routine clinical practice? Clin Kidney J. 2023;16:1199\u2013205. https:\/\/doi.org\/10.1093\/ckj\/sfad122.","journal-title":"Clin Kidney J"},{"key":"742_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2215\/CJN.08970719","volume":"15","author":"A Uffing","year":"2020","unstructured":"Uffing A, P\u00e9rez-S\u00e1ez MJ, Mazzali M, Manfro RC, Bauer AC, Drumond FdeS, et al. Recurrence of FSGS after kidney transplantation in adults. Clin J Am Soc Nephrol. 2020;15:247\u201356. https:\/\/doi.org\/10.2215\/CJN.08970719.","journal-title":"Clin J Am Soc Nephrol"},{"key":"742_CR45","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1111\/ajt.16504","volume":"21","author":"C Lanaret","year":"2021","unstructured":"Lanaret C, Anglicheau D, Audard V, B\u00fcchler M, Caillard S, Couzi L, et al. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: results of a nationwide study. Am J Transplant. 2021;21:3021\u201333. https:\/\/doi.org\/10.1111\/ajt.16504.","journal-title":"Am J Transplant"},{"key":"742_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/TP.0b013e3181aed9d7","volume":"88","author":"SL Dello","year":"2009","unstructured":"Dello SL, Guzzo I, Laurenzi C, Vivarelli M, Parodi A, Barbano G, et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation. 2009;88:417\u201320. https:\/\/doi.org\/10.1097\/TP.0b013e3181aed9d7.","journal-title":"Transplantation"},{"key":"742_CR47","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1097\/TP.0000000000002008","volume":"102","author":"S Alasfar","year":"2018","unstructured":"Alasfar S, Matar D, Montgomery RA, Desai N, Lonze B, Vujjini V, et al. Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation. Transplantation. 2018;102:e115\u201320. https:\/\/doi.org\/10.1097\/TP.0000000000002008.","journal-title":"Transplantation"},{"key":"742_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf058","author":"S Gharaei","year":"2025","unstructured":"Gharaei S, Gharaei J, Ragy O, Kanigicherla DAK. Use of rituximab and plasma exchange in treatment and prophylaxis of recurrent FSGS. Clin Kidney J. 2025. https:\/\/doi.org\/10.1093\/ckj\/sfaf058.","journal-title":"Clin Kidney J"},{"key":"742_CR49","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1093\/ndt\/gfq256","volume":"25","author":"F Catapano","year":"2010","unstructured":"Catapano F, Chaudhry AN, Jones RB, Smith KGC, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25:3586\u201392. https:\/\/doi.org\/10.1093\/ndt\/gfq256.","journal-title":"Nephrol Dial Transplant"},{"key":"742_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222\u201333. https:\/\/doi.org\/10.1002\/art.27233.","journal-title":"Arthritis Rheum"},{"key":"742_CR51","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215\u201326. https:\/\/doi.org\/10.1002\/art.34359.","journal-title":"Arthritis Rheum"},{"key":"742_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.10.018","author":"AS De Vriese","year":"2024","unstructured":"De Vriese AS, Sethi S, Fervenza FC. Lupus nephritis: redefining the treatment goals. Kidney Int. 2024. https:\/\/doi.org\/10.1016\/j.kint.2024.10.018.","journal-title":"Kidney Int"},{"key":"742_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152346","author":"M Rodziewicz","year":"2024","unstructured":"Rodziewicz M, Mendoza-Pinto C, Dyball S, Mungu\u00eda-Realpozo P, Parker B, Bruce IN. Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: a systematic review update. Semin Arthritis Rheum. 2024. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152346.","journal-title":"Semin Arthritis Rheum"},{"key":"742_CR54","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000520","author":"P Gauckler","year":"2024","unstructured":"Gauckler P, Matyjek A, Kapsia S, Marinaki S, Quintana LF, Diaz MM, et al. Long-term outcomes of Rituximab-treated adult patients with podocytopathies. J Am Soc Nephrol. 2024. https:\/\/doi.org\/10.1681\/ASN.0000000520.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR55","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306\u201313.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR56","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2169\/internalmedicine.52.9325","volume":"52","author":"H Ishiguro","year":"2013","unstructured":"Ishiguro H, Hashimoto T, Akata M, Suzuki S, Azushima K, Kobayashi Y, et al. Rituximab treatment for adult purpura nephritis with nephrotic syndrome. Intern Med. 2013;52:1079\u201383. https:\/\/doi.org\/10.2169\/internalmedicine.52.9325.","journal-title":"Intern Med"},{"key":"742_CR57","unstructured":"Fenoglio R, Sciascia S, Naretto C, De E, Giulio S, Vecchio D, et al. S-195. vol. 38. 2020."},{"key":"742_CR58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.40339","volume":"70","author":"F Maritati","year":"2018","unstructured":"Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R, et al. Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Sch\u00f6nlein). Arthritis Rheumatol. 2018;70:109\u201314. https:\/\/doi.org\/10.1002\/art.40339.","journal-title":"Arthritis Rheumatol"},{"key":"742_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae178","author":"M Sun","year":"2024","unstructured":"Sun M, Wang L, Liu X, Xiao F, Dai H. The successful use of rituximab in IgA nephropathy patients with podocytopathy: a case series. Clin Kidney J. 2024. https:\/\/doi.org\/10.1093\/ckj\/sfae178.","journal-title":"Clin Kidney J"},{"key":"742_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/ckj\/sfw106","volume":"10","author":"S Lundberg","year":"2017","unstructured":"Lundberg S, Westergren E, Smolander J, Bruchfeld A. B cell depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J. 2017;10:20\u20136. https:\/\/doi.org\/10.1093\/ckj\/sfw106.","journal-title":"Clin Kidney J"},{"key":"742_CR61","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1053\/j.ajkd.2025.01.009","volume":"85","author":"L Bu","year":"2025","unstructured":"Bu L, Valeri AM, Said SM, Zhu Y, Herrera Hernandez L, Gladish R, et al. IgM variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a case series. Am J Kidney Dis. 2025;85:716-726.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2025.01.009.","journal-title":"Am J Kidney Dis"},{"key":"742_CR62","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/ckj\/sfx001","volume":"10","author":"B Merhi","year":"2017","unstructured":"Merhi B, Patel N, Bayliss G, Henriksen KJ, Gohh R. Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab. Clin Kidney J. 2017;10:405\u201310. https:\/\/doi.org\/10.1093\/ckj\/sfx001.","journal-title":"Clin Kidney J"},{"key":"742_CR63","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/TP.0000000000002577","volume":"103","author":"A Buxeda","year":"2019","unstructured":"Buxeda A, Said SM, Nasr SH, Leung N, El Ters M, Cosio FG. Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin deposits in kidney allografts treated with anti-CD20 antibodies. Transplantation. 2019;103:1477\u201385. https:\/\/doi.org\/10.1097\/TP.0000000000002577.","journal-title":"Transplantation"},{"key":"742_CR64","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2215\/CJN.03870319","volume":"14","author":"NK Andeen","year":"2019","unstructured":"Andeen NK, Troxell ML, Riazy M, Avasare RS, Lapasia J, Jefferson JA, et al. Fibrillary glomerulonephritis clinicopathologic features and atypical cases from a multi-institutional cohort. Clin J Am Soc Nephrol. 2019;14:1741\u201350. https:\/\/doi.org\/10.2215\/CJN.03870319.","journal-title":"Clin J Am Soc Nephrol"},{"key":"742_CR65","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024b9tnzz8b","author":"G Sauvage","year":"2024","unstructured":"Sauvage G, Zonozi R, Efe O, Jeyabalan A, Cosgrove KM, Laliberte KA, et al. Fibrillary glomerulonephritis treated with rituximab and cyclophosphamide combination therapy: a retrospective cohort study. J Am Soc Nephrol. 2024. https:\/\/doi.org\/10.1681\/ASN.2024b9tnzz8b.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR66","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.34067\/KID.0002532020","volume":"1","author":"N Klomjit","year":"2020","unstructured":"Klomjit N, Alexander MP, Zand L. Fibrillary glomerulonephritis and DnaJ homolog subfamily B member 9 (DNAJB9). Kidney360. 2020;1:1002\u201313. https:\/\/doi.org\/10.34067\/KID.0002532020.","journal-title":"Kidney360"},{"key":"742_CR67","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/NDT\/GFAA065","volume":"36","author":"SB Erickson","year":"2021","unstructured":"Erickson SB, Zand L, Nasr SH, Alexander MP, Leung N, Drosou ME, et al. Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study. Nephrol Dial Transplant. 2021;36:104\u201310. https:\/\/doi.org\/10.1093\/NDT\/GFAA065.","journal-title":"Nephrol Dial Transplant"},{"key":"742_CR68","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00467-020-04570-y","volume":"35","author":"JA Kari","year":"2020","unstructured":"Kari JA, Alhasan KA, Albanna AS, Safdar OY, Shalaby MA, B\u00f6ckenhauer D, et al. Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2020;35:1445\u201353. https:\/\/doi.org\/10.1007\/s00467-020-04570-y.","journal-title":"Pediatr Nephrol"},{"key":"742_CR69","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2215\/CJN.08570722","volume":"18","author":"EYH Chan","year":"2023","unstructured":"Chan EYH, Yap DYH, Colucci M, Ma ALT, Parekh RS, Tullus K. Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol. 2023;18:533\u201348. https:\/\/doi.org\/10.2215\/CJN.08570722.","journal-title":"Clin J Am Soc Nephrol"},{"key":"742_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.12.025","author":"M Vivarelli","year":"2025","unstructured":"Vivarelli M, Colucci M. Rituximab as first-line steroid-sparing agent in pediatric nephrotic syndrome: too early? Kidney Int. 2025. https:\/\/doi.org\/10.1016\/j.kint.2024.12.025.","journal-title":"Kidney Int"},{"key":"742_CR71","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/nejmoa2314471","volume":"391","author":"FE Hengel","year":"2024","unstructured":"Hengel FE, Dehde S, Lass\u00e9 M, Zahner G, Seifert L, Schnarre A, et al. Autoantibodies targeting Nephrin in podocytopathies. N Engl J Med. 2024;391:422\u201333. https:\/\/doi.org\/10.1056\/nejmoa2314471.","journal-title":"N Engl J Med"},{"key":"742_CR72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jpeds.2018.01.008","volume":"197","author":"M Jellouli","year":"2018","unstructured":"Jellouli M, Charfi R, Maalej B, Mahfoud A, Trabelsi S, Gargah T. Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: a systematic review. J Pediatr. 2018;197:191-197.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2018.01.008.","journal-title":"J Pediatr"},{"key":"742_CR73","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1681\/ASN.2012040413","volume":"23","author":"M Pradhan","year":"2012","unstructured":"Pradhan M, Furth S. Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope? J Am Soc Nephrol. 2012;23:975\u20138. https:\/\/doi.org\/10.1681\/ASN.2012040413.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR74","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"MC Chaumais","year":"2009","unstructured":"Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009;24:1753\u20135. https:\/\/doi.org\/10.1007\/s00467-009-1195-9.","journal-title":"Pediatr Nephrol"},{"key":"742_CR75","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3.","journal-title":"Pediatr Nephrol"},{"key":"742_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae348","author":"X Zhang","year":"2025","unstructured":"Zhang X, Jin Y, Liu F, Li Q, Xie Y, Huang G, et al. Rituximab as a first-line therapy in children with new-onset idiopathic nephrotic syndrome. Clin Kidney J. 2025. https:\/\/doi.org\/10.1093\/ckj\/sfae348.","journal-title":"Clin Kidney J"},{"key":"742_CR77","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","volume":"76","author":"MY Md Yusof","year":"2017","unstructured":"Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76:1829\u201336. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211191.","journal-title":"Ann Rheum Dis"},{"key":"742_CR78","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/rheumatology\/keac608","volume":"62","author":"C Wincup","year":"2023","unstructured":"Wincup C, Dunn N, Ruetsch-Chelli C, Manouchehrinia A, Kharlamova N, Naja M, et al. Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus. Rheumatology. 2023;62:2601\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/keac608.","journal-title":"Rheumatology"},{"key":"742_CR79","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1136\/annrheumdis-2019-215200","volume":"78","author":"C Wincup","year":"2019","unstructured":"Wincup C, Menon M, Smith E, Schwartz A, Isenberg D, Jury EC, et al. Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1140\u20132. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215200.","journal-title":"Ann Rheum Dis"},{"key":"742_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00498","author":"SU Hassan","year":"2020","unstructured":"Hassan SU, Md Yusof MY, Emery P, Dass S, Vital EM. Biologic sequencing in systemic lupus erythematosus: after secondary non-response to rituximab, switching to humanised anti-CD20 agent is more effective than belimumab. Front Med (Lausanne). 2020. https:\/\/doi.org\/10.3389\/fmed.2020.00498.","journal-title":"Front Med (Lausanne)"},{"key":"742_CR81","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00467-021-05069-w","volume":"37","author":"Q Bertrand","year":"2022","unstructured":"Bertrand Q, Mignot S, Kwon T, Couderc A, Maisin A, Cambier A, et al. Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2022;37:357\u201365. https:\/\/doi.org\/10.1007\/s00467-021-05069-w.","journal-title":"Pediatr Nephrol"},{"key":"742_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/lymphatics2010002","volume":"2","author":"H Mahadevia","year":"2024","unstructured":"Mahadevia H, Ananthamurugan M, Shah K, Desai A, Shrestha A. A review of anti-CD20 antibodies in the management of B-cell lymphomas. Lymphatics. 2024;2:10\u201324. https:\/\/doi.org\/10.3390\/lymphatics2010002.","journal-title":"Lymphatics"},{"key":"742_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03069","author":"S Boyer-Suavet","year":"2020","unstructured":"Boyer-Suavet S, Andreani M, Lateb M, Savenkoff B, Brglez V, Benzaken S, et al. Neutralizing anti-Rituximab antibodies and relapse in membranous nephropathy treated with Rituximab. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2019.03069.","journal-title":"Front Immunol"},{"key":"742_CR84","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","volume":"10","author":"M Teisseyre","year":"2025","unstructured":"Teisseyre M, Allinovi M, Audard V, Cremoni M, Belvederi G, Karam\u00e9 A, et al. Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies. Kidney Int Rep. 2025;10:753\u201361. https:\/\/doi.org\/10.1016\/j.ekir.2024.12.012.","journal-title":"Kidney Int Rep"},{"key":"742_CR85","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12291-017-0643-8","volume":"33","author":"SN Chakravarthy","year":"2018","unstructured":"Chakravarthy SN, Ramanathan S, Menon S, Valappil V, Durairaj M, Arokia J. Cinderella in serum protein electrophoresis. Indian J Clin Biochem. 2018;33:113\u20136. https:\/\/doi.org\/10.1007\/s12291-017-0643-8.","journal-title":"Indian J Clin Biochem"},{"key":"742_CR86","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.3324\/haematol.2017.171694","volume":"102","author":"MD Jawad","year":"2017","unstructured":"Jawad MD, Go RS, Witzig TE, Mikhae JR, Ravindran A, Murrray DL. Pseudo-monoclonal gammopathy: a report of four cases. Haematologica. 2017;102:e466\u20139. https:\/\/doi.org\/10.3324\/haematol.2017.171694.","journal-title":"Haematologica"},{"key":"742_CR87","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00545-16","author":"PM Ladwig","year":"2017","unstructured":"Ladwig PM, Barnidge DR, Willrich MAV. Mass spectrometry approaches for identification and quantitation of therapeutic monoclonal antibodies in the clinical laboratory. Clin Vaccine Immunol. 2017. https:\/\/doi.org\/10.1128\/CVI.00545-16.","journal-title":"Clin Vaccine Immunol"},{"key":"742_CR88","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling JL, French RR, Cragg MS, Van Den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793\u2013800. https:\/\/doi.org\/10.1182\/blood-2004-01-0039.","journal-title":"Blood"},{"key":"742_CR89","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","volume":"14","author":"JML Casan","year":"2018","unstructured":"Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14:2820\u201341. https:\/\/doi.org\/10.1080\/21645515.2018.1508624.","journal-title":"Hum Vaccin Immunother"},{"key":"742_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1024068","author":"JM Hartinger","year":"2022","unstructured":"Hartinger JM, Kratky V, Hruskova Z, Slanar O, Tesar V. Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.1024068.","journal-title":"Front Immunol"},{"key":"742_CR91","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","volume":"111","author":"A Hagenbeek","year":"2008","unstructured":"Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial. Blood. 2008;111:5486\u201395. https:\/\/doi.org\/10.1182\/blood-2007-10-117671.","journal-title":"Blood"},{"key":"742_CR92","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/j.1349-7006.2009.01222.x","volume":"100","author":"T Kubota","year":"2009","unstructured":"Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009;100:1566\u201372. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01222.x.","journal-title":"Cancer Sci"},{"key":"742_CR93","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bcp.13029","volume":"82","author":"A Bonanni","year":"2016","unstructured":"Bonanni A, Bertelli E, Moscatelli A, Lampugnani E, Bodria M, Ravani P, et al. Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment. Br J Clin Pharmacol. 2016;82:1146\u20138. https:\/\/doi.org\/10.1111\/bcp.13029.","journal-title":"Br J Clin Pharmacol"},{"key":"742_CR94","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","volume":"45","author":"P Karmacharya","year":"2015","unstructured":"Karmacharya P, Poudel DR, Pathak R, Donato AA, Ghimire S, Giri S, et al. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum. 2015;45:334\u201340. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.014.","journal-title":"Semin Arthritis Rheum"},{"key":"742_CR95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","volume":"67","author":"G Bayer","year":"2019","unstructured":"Bayer G, Agier MS, Lioger B, Lepelley M, Zenut M, Lanoue MC, et al. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study. Eur J Intern Med. 2019;67:59\u201364. https:\/\/doi.org\/10.1016\/j.ejim.2019.06.009.","journal-title":"Eur J Intern Med"},{"key":"742_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-232896","author":"MA Podest\u00e0","year":"2020","unstructured":"Podest\u00e0 MA, Ruggiero B, Remuzzi G, Ruggenenti P. Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. BMJ Case Rep. 2020. https:\/\/doi.org\/10.1136\/bcr-2019-232896.","journal-title":"BMJ Case Rep"},{"key":"742_CR97","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00467-020-04567-7","volume":"35","author":"J Bernard","year":"2020","unstructured":"Bernard J, Lalieve F, Sarlat J, Perrin J, Dehoux L, Boyer O, et al. Ofatumumab treatment for nephrotic syndrome recurrence after pediatric renal transplantation. Pediatr Nephrol. 2020;35:1499\u2013506. https:\/\/doi.org\/10.1007\/s00467-020-04567-7.","journal-title":"Pediatr Nephrol"},{"key":"742_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf083","author":"S Pollack","year":"2025","unstructured":"Pollack S, Plonsky-Toder M, Tibi R, Libinson-Zebegret I, Yakobov R, Magen D. Subcutaneous ofatumumab in recurrent focal segmental glomerulosclerosis after kidney transplantation. Clin Kidney J. 2025. https:\/\/doi.org\/10.1093\/ckj\/sfaf083.","journal-title":"Clin Kidney J"},{"key":"742_CR99","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/rheumatology\/kew199","volume":"55","author":"SP McAdoo","year":"2016","unstructured":"McAdoo SP, Bedi R, Tarzi R, Griffith M, Pusey CD, Cairns TD. Ofatumumab for B cell depletion therapy in ANCAassociated vasculitis: a single-centre case series. Rheumatology. 2016;55:1437\u201342. https:\/\/doi.org\/10.1093\/rheumatology\/kew199.","journal-title":"Rheumatology"},{"key":"742_CR100","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","volume":"83","author":"MA Podest\u00e0","year":"2024","unstructured":"Podest\u00e0 MA, Trillini M, Portalupi V, Gennarini A, Tomatis F, Villa A, et al. Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series. Am J Kidney Dis. 2024;83:340-349.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2023.08.010.","journal-title":"Am J Kidney Dis"},{"key":"742_CR101","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/ckj\/sfw022","volume":"9","author":"ML Haarhaus","year":"2016","unstructured":"Haarhaus ML, Svenungsson E, Gunnarsson I. Ofatumumab treatment in lupus nephritis patients. Clin Kidney J. 2016;9:552\u20135. https:\/\/doi.org\/10.1093\/ckj\/sfw022.","journal-title":"Clin Kidney J"},{"key":"742_CR102","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","volume":"57","author":"S Masoud","year":"2018","unstructured":"Masoud S, McAdoo SP, Bedi R, Cairns TD, Lightstone L. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology. 2018;57:1156\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/key042.","journal-title":"Rheumatology"},{"key":"742_CR103","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/rheumatology\/keu475","volume":"54","author":"CC Thornton","year":"2015","unstructured":"Thornton CC, Ambrose N, Ioannou Y. Ofatumumab: a novel treatment for severe systemic lupus erythematosus. Rheumatology. 2015;54:559\u201360. https:\/\/doi.org\/10.1093\/rheumatology\/keu475.","journal-title":"Rheumatology"},{"key":"742_CR104","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","volume":"21","author":"F Morschhauser","year":"2010","unstructured":"Morschhauser F, Marlton P, Vitolo U, Lind\u00e9n O, Seymour JF, Crump M, et al. Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma. Ann Oncol. 2010;21:1870\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdq027.","journal-title":"Ann Oncol"},{"key":"742_CR105","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1016\/j.molimm.2008.01.034","volume":"45","author":"J Du","year":"2008","unstructured":"Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol. 2008;45:2861\u20138. https:\/\/doi.org\/10.1016\/j.molimm.2008.01.034.","journal-title":"Mol Immunol"},{"key":"742_CR106","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","volume":"65","author":"EF Mysler","year":"2013","unstructured":"Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65:2368\u201379. https:\/\/doi.org\/10.1002\/art.38037.","journal-title":"Arthritis Rheum"},{"key":"742_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109265","author":"CM Looney","year":"2023","unstructured":"Looney CM, Strauli N, Cascino MD, Garma H, Schroeder AV, Takahashi C, et al. Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell\u2013depleting agents. Clin Immunol. 2023. https:\/\/doi.org\/10.1016\/j.clim.2023.109265.","journal-title":"Clin Immunol"},{"key":"742_CR108","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/nejmoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101\u201310. https:\/\/doi.org\/10.1056\/nejmoa1313984.","journal-title":"N Engl J Med"},{"key":"742_CR109","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.41608","volume":"73","author":"AD Marinov","year":"2021","unstructured":"Marinov AD, Wang H, Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, et al. The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. Arthritis Rheumatol. 2021;73:826\u201336. https:\/\/doi.org\/10.1002\/art.41608.","journal-title":"Arthritis Rheumatol"},{"key":"742_CR110","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-11-0850","volume":"18","author":"A Forero-Torres","year":"2012","unstructured":"Forero-Torres A, De Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in Fc\u03b3RIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012;18:1395\u2013403. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0850.","journal-title":"Clin Cancer Res"},{"key":"742_CR111","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-03-0493","author":"R Stein","year":"2004","unstructured":"Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, Epratuzumab, for the therapy of non-Hodgkin\u2019s lymphoma. Clin Cancer Res. 2004. https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0493.","journal-title":"Clin Cancer Res"},{"key":"742_CR112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05","author":"J Jos","year":"2013","unstructured":"Jos J, Golay J, Roit FD, Bologna L, Ferrara C, Leusen JH, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab Key Points. Blood. 2013. https:\/\/doi.org\/10.1182\/blood-2013-05.","journal-title":"Blood"},{"key":"742_CR113","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3324\/haematol.2015.133421","volume":"101","author":"G Cartron","year":"2016","unstructured":"Cartron G, Hourcade-Potelleret F, Morschhauser F, Salles G, Wenger M, Truppel-Hartmann A, et al. Rationale for optimal obinutuzumab\/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica. 2016;101:226\u201334. https:\/\/doi.org\/10.3324\/haematol.2015.133421.","journal-title":"Haematologica"},{"key":"742_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.42","author":"E Gibiansky","year":"2014","unstructured":"Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N. Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin\u2019s lymphoma and exposure-response in CLL. CPT Pharmacometrics Syst Pharmacol. 2014. https:\/\/doi.org\/10.1038\/psp.2014.42.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"742_CR115","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1007\/s11033-022-07280-w","volume":"49","author":"N Kawasaki","year":"2022","unstructured":"Kawasaki N, Yamashita-Kashima Y, Fujimura T, Yoshiura S, Harada N, Kondoh O, et al. Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies. Mol Biol Rep. 2022;49:4421\u201333. https:\/\/doi.org\/10.1007\/s11033-022-07280-w.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"742_CR116","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920.","journal-title":"Ann Rheum Dis"},{"key":"742_CR117","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","volume":"451","author":"R Jacobs","year":"2017","unstructured":"Jacobs R, Langer-Jacobus T, Duong M, Stahl K, Haller H, Schmidt RE, et al. Detection and quantification of rituximab in the human urine. J Immunol Methods. 2017;451:118\u201321. https:\/\/doi.org\/10.1016\/j.jim.2017.09.001.","journal-title":"J Immunol Methods"},{"key":"742_CR118","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf127\/8191243","author":"M Allinovi","year":"2025","unstructured":"Allinovi M, Accinno M, Finocchi C, Mazzierli T, Caroti L, Lazzarini D, et al. Urinary rituximab loss and rate of treatment failure in membranous nephropathy. Nephrol Dial Transplant. 2025. https:\/\/doi.org\/10.1093\/ndt\/gfaf127\/8191243.","journal-title":"Nephrol Dial Transplant"},{"key":"742_CR119","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/art.42734","volume":"76","author":"BH Rovin","year":"2024","unstructured":"Rovin BH, Furie RA, Ross Terres JA, Giang S, Schindler T, Turchetta A, et al. Kidney outcomes and preservation of kidney function with Obinutuzumab in patients with lupus nephritis: a post hoc analysis of the NOBILITY trial. Arthritis Rheumatol. 2024;76:247\u201354. https:\/\/doi.org\/10.1002\/art.42734.","journal-title":"Arthritis Rheumatol"},{"key":"742_CR120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410965","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Mart\u00ednez G, Zuta Santill\u00e1n AE, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2410965.","journal-title":"N Engl J Med"},{"key":"742_CR121","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","volume":"18","author":"C Dossier","year":"2023","unstructured":"Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, et al. Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children. Clin J Am Soc Nephrol. 2023;18:1555\u201362. https:\/\/doi.org\/10.2215\/CJN.0000000000000288.","journal-title":"Clin J Am Soc Nephrol"},{"key":"742_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.06.010","author":"P Randone","year":"2024","unstructured":"Randone P, Sanna E, Dolla C, Gallo E, Mingozzi S, Tarragoni R, et al. Rescue with obinutuzumab and daratumumab as combined B cell\/plasma cell targeting approach in severe posttransplant focal segmental glomerulosclerosis recurrence. Am J Transplant. 2024. https:\/\/doi.org\/10.1016\/j.ajt.2024.06.010.","journal-title":"Am J Transplant"},{"key":"742_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110240","author":"E Favi","year":"2024","unstructured":"Favi E, Cresseri D, Perego M, Ikehata M, Iesari S, Campise MR, et al. Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: a proof of concept. Clin Immunol. 2024. https:\/\/doi.org\/10.1016\/j.clim.2024.110240.","journal-title":"Clin Immunol"},{"key":"742_CR124","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/TP.0000000000003686","volume":"106","author":"MM NasrAllah","year":"2022","unstructured":"NasrAllah MM, Elalfy M, El Ansary M, Elmeseery Y, Amer I, Malvezzi P, et al. Obinutuzumab in kidney transplantation: effect on B-cell counts and crossmatch tests. Transplantation. 2022;106:369\u201372. https:\/\/doi.org\/10.1097\/TP.0000000000003686.","journal-title":"Transplantation"},{"key":"742_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030041","volume":"9","author":"AC Velazquez","year":"2020","unstructured":"Velazquez AC, Iturrieta-Zuazo I, Shephard JLV, Natale MD, Rita C, Gonz\u00e1lez RB, et al. Solutions to avoid false positives for rituximab in pre-transplant crossmatches. Antibodies. 2020;9:1\u20136. https:\/\/doi.org\/10.3390\/antib9030041.","journal-title":"Antibodies"},{"key":"742_CR126","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.humimm.2004.06.001","volume":"65","author":"CM Bearden","year":"2004","unstructured":"Bearden CM, Agarwal A, Book BK, Sidner RA, Gebel HM, Bray RA, et al. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol. 2004;65:803\u20139. https:\/\/doi.org\/10.1016\/j.humimm.2004.06.001.","journal-title":"Hum Immunol"},{"key":"742_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100853","author":"Y Lin","year":"2024","unstructured":"Lin Y, Han Q, Chen L, Wang Y, Ren P, Liu G, et al. Obinutuzumab in refractory membranous nephropathy: a case series. Kidney Med. 2024. https:\/\/doi.org\/10.1016\/j.xkme.2024.100853.","journal-title":"Kidney Med"},{"key":"742_CR128","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","volume":"76","author":"N Klomjit","year":"2020","unstructured":"Klomjit N, Fervenza FC, Zand L. Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases. Am J Kidney Dis. 2020;76:883\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.444.","journal-title":"Am J Kidney Dis"},{"key":"742_CR129","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae299","author":"M Xu","year":"2024","unstructured":"Xu M, Chen R, Wang Y, Huang X, Zhang H, Zhao W, et al. Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic. Clin Kidney J. 2024. https:\/\/doi.org\/10.1093\/ckj\/sfae299.","journal-title":"Clin Kidney J"},{"key":"742_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.12.012","author":"M Teisseyre","year":"2025","unstructured":"Teisseyre M, Allinovi M, Audard V, Cremoni M, Belvederi G, Karam\u00e9 A, et al. Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies. Kidney Int Rep. 2025. https:\/\/doi.org\/10.1016\/j.ekir.2024.12.012.","journal-title":"Kidney Int Rep"},{"key":"742_CR131","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/ndt\/gfae230","volume":"40","author":"M Xu","year":"2025","unstructured":"Xu M, Wang Y, Wu M, Chen R, Zhao W, Li M, et al. Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy. Nephrol Dial Transplant. 2025;40:978\u201386. https:\/\/doi.org\/10.1093\/ndt\/gfae230.","journal-title":"Nephrol Dial Transplant"},{"key":"742_CR132","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","volume":"61","author":"NA Amudala","year":"2022","unstructured":"Amudala NA, Boukhlal S, Sheridan B, Langford CA, Geara A, Merkel PA, et al. Obinutuzumab as treatment for ANCA-associated vasculitis. Rheumatology. 2022;61:3814\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keab916.","journal-title":"Rheumatology"},{"key":"742_CR133","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083277","author":"DP McGovern","year":"2024","unstructured":"McGovern DP, McClure ME, Coates M, Bond S, Martinez Del Pero M, Mynard K, et al. Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas. BMJ Open. 2024. https:\/\/doi.org\/10.1136\/bmjopen-2023-083277.","journal-title":"BMJ Open"},{"key":"742_CR134","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bjh.18826","volume":"202","author":"Y Mechelfekh","year":"2023","unstructured":"Mechelfekh Y, Pontrucher A, Paillassa J, Temple M, Houot R. Obinutuzumab-induced acute thrombocytopenia: report of two cases and review of literature. Br J Haematol. 2023;202:168\u201372. https:\/\/doi.org\/10.1111\/bjh.18826.","journal-title":"Br J Haematol"},{"key":"742_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102702","author":"Y Shi","year":"2024","unstructured":"Shi Y, Zhou K, Zhou H, Qin Y, Jing H, Xiang Y, et al. Efficacy and safety of MIL62, a novel glycoengineered type \u2161 anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed\/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b\/2 trial. EClinMed. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102702.","journal-title":"EClinMed"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00742-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:26:37Z","timestamp":1761704797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00742-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":135,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["742"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00742-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"25 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The original contributions presented in the study are included in the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data avilability"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"FY, FF, and FC-F wrote the manuscript. All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}